Disease · MONDO_0008903
Comparisons in its trials42
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 42
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Necitumumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause | 476 of 538 | 487 of 541 | 1,079 | NCT00981058 | Trial comparisons |
| Necitumumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: serious adverse events | 262 of 538 | 208 of 541 | 1,079 | NCT00981058 | Trial comparisons |
| CT-P16 vs Avastin: deaths from any cause | 24 of 345 | 25 of 344 | 689 | NCT03676192 | Trial comparisons |
| CT-P16 vs Avastin: serious adverse events | 69 of 345 | 73 of 344 | 689 | NCT03676192 | Trial comparisons |
| Atezolizumab vs Atezolizumab+ Lurbinectedin: Randomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab | 20 of 239 | 19 of 242 | 481 | NCT05091567 | Trial comparisons |
| Abemaciclib vs Erlotinib: deaths from any cause | 186 of 265 | 123 of 175 | 440 | NCT02152631 | Trial comparisons |
| Abemaciclib vs Erlotinib: serious adverse events | 112 of 265 | 43 of 175 | 440 | NCT02152631 | Trial comparisons |
| Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo: Major Pathologic Response (MPR) Rate | 16 of 179 | 66 of 179 | 358 | NCT02998528 | Trial comparisons |
| Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo: Pathologic Complete Response (pCR) Rate | 4 of 179 | 43 of 179 | 358 | NCT02998528 | Trial comparisons |
| Part 1: Treatment A vs Part 1: Treatment B: Number of Participants With a Treatment Related AEs in Part 1 | 75 of 77 | 76 of 79 | 156 | NCT04623775 | Trial comparisons |
| Arm I - Quitline vs Arm II - Usual Care: Feasibility of a Smoking Cessation Intervention Among Cancer Patients | 55 of 98 | 33 of 48 | 146 | NCT01434342 | Trial comparisons |
Ipilimumab/Placebo + Paclitaxil/Carboplatin (Concurrent) vs Ipilimumab + Paclitaxel/Carboplatin (Sequential): Number of Participants With NSCLC Who Have Positive Human Antihuman Antibody (HAHA) Status Postbaseline | 2 of 61 | 1 of 56 | 117 | NCT00527735 | Trial comparisons |
| Arm I - Quitline vs Arm II - Usual Care: serious adverse events | 14 of 75 | 5 of 37 | 112 | NCT01434342 | Trial comparisons |
| Nivolumab 3mg/kg IV Every 2 Weeks vs Stereotactic Body Radiotherapy & Nivolumab: deaths from any cause | 26 of 32 | 27 of 33 | 65 | NCT02684253 | Trial comparisons |
| Nivolumab 3mg/kg IV Every 2 Weeks vs Stereotactic Body Radiotherapy & Nivolumab: serious adverse events | 4 of 32 | 3 of 33 | 65 | NCT02684253 | Trial comparisons |
| Dabrafenib in Combination With Trametinib (On-treatment Period) vs Dabrafenib in Combination With Trametinib (Post-treatment Follow-up Phase): deaths from any cause | 6 of 40 | 12 of 16 | 56 | NCT04452877 | Trial comparisons |
| Dabrafenib in Combination With Trametinib (On-treatment Period) vs Dabrafenib in Combination With Trametinib (Post-treatment Follow-up Phase): serious adverse events | 20 of 40 | 1 of 16 | 56 | NCT04452877 | Trial comparisons |
Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 47 of 47 | 3 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: deaths from any cause | 28 of 47 | 0 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: serious adverse events | 18 of 47 | 1 of 3 | 50 | NCT04287868 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008903/comparisons